Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025 Life Science Investing
Exelixis to Webcast Virtual 2025 Research & Development Day on Wednesday, December 10, 2025 Life Science Investing
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities Life Science Investing
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation Life Science Investing
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date Life Science Investing
New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF Life Science Investing
New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF Life Science Investing
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination Life Science Investing
Nextech3D.ai Announces Definitive Agreement to Acquire 100% of ARway, Streamlining Operations Artificial Intelligence Investing
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise Life Science Investing
